# Carotenoid dietary intakes and plasma concentrations are associated with heel bone ultrasound attenuation and osteoporotic fracture risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort

Richard P. G. Hayhoe<sup>1</sup>\*, Marleen A. H. Lentjes<sup>2</sup>, Angela A. Mulligan<sup>2</sup>, Robert N. Luben<sup>2</sup>, Kay-Tee Khaw<sup>2</sup> and Ailsa A. Welch<sup>1</sup>

<sup>1</sup>Department of Population Health and Primary Care, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich NR4 7TJ, UK

<sup>2</sup>Strangeways Research Laboratory, Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK

(Submitted 24 October 2016 – Final revision received 30 March 2017 – Accepted 26 April 2017)

#### Abstract

Carotenoids are found in abundance in fruit and vegetables, and may be involved in the positive association of these foods with bone health. This study aimed to explore the associations of dietary carotenoid intakes and plasma concentrations with bone density status and osteoporotic fracture risk in a European population. Cross-sectional analyses (n 14803) of bone density status, using calcaneal broadband ultrasound attenuation (BUA) and longitudinal analyses (n 25 439) of fracture cases were conducted on data from the prospective European Prospective Investigation into Cancer and Nutrition-Norfolk cohort of middle-aged and older men and women. Health and lifestyle questionnaires were completed, and dietary nutrient intakes were derived from 7-d food diaries. Multiple regression demonstrated significant positive trends in BUA for women across quintiles of dietary  $\alpha$ -carotene intake (P=0.029),  $\beta$ -carotene intake (P=0.0031), combined lutein and zeaxanthin intake (P=0.010) and lycopene intake (P=0.005). No significant trends across plasma carotenoid concentration quintiles (mean follow-up time 12.5 years), except for a lower risk for wrist fracture in women with higher lutein and zeaxanthin intake (P=0.022); nevertheless, inter-quintile differences in fracture risk were found for both sexes. Analysis of plasma carotenoid data (mean follow-up time 11.9 years) showed lower hip fracture risk in men across higher plasma  $\alpha$ -carotene (P=0.026) and  $\beta$ -carotene (P=0.027) quintiles. This study provides novel evidence that dietary carotenoid intake is relevant to bone health in men and women, demonstrating that associations with bone density status and fracture risk exist for dietary intake of specific carotenoids and their plasma concentrations.

### Key words: Carotenoids: Nutrition: Bone ultrasound: Fractures: Osteoporosis

Nutrition is an important modifiable factor influencing bone health<sup>(1)</sup>, and thus an optimised diet could help reduce age-related osteoporotic bone deterioration and risk for fracture, an increasingly critical issue in our ageing population. The significance of dietary Ca and vitamin D to bone, especially during development, has been well established in the literature<sup>(2)</sup>, although the true benefits of supplementation in later life has been subject to recent debate<sup>(3)</sup>. Research has now begun to appreciate that other nutrients may be similarly important. In particular, growing evidence supports the importance of micronutrients and antioxidants abundant in fruit and vegetables, including Mg, K<sup>(4)</sup> and vitamin C<sup>(5)</sup>.

Carotenoids are a class of phytochemicals found in particular abundance in yellow–orange and dark-green leafy vegetables<sup>(6)</sup>.

Their chemical structure contains a conjugated double-bond chain forming a chromophore, which confers a specific colour, for example, yellow (lutein), orange ( $\beta$ -carotene) or red (lycopene), and provides antioxidant properties and the potential for energy transfer reactions<sup>(6)</sup>. They were originally hypothesised to exert their effects on bone via provitamin A activity, as vitamin A, in its active form as retinoic acid, is known to regulate the balance between osteoblastic bone formation and osteoclastic bone resorption, to up-regulate vitamin D receptors, and to have an anabolic effect on bone, except at high doses where it may accelerate bone resorption<sup>(77)</sup>. However, some carotenoids (lutein, zeaxanthin and lycopene) do not possess provitamin A carotenoids on bone health supports the concept

Abbreviations: BUA, broadband ultrasound attenuation; HRT, hormone replacement therapy.



<sup>\*</sup> Corresponding author: Dr R. P. G. Hayhoe, email r.hayhoe@uea.ac.uk

2

of a mechanism independent of vitamin A. Reactive O species have been shown by *in vitro* experiments, including those using human cell lines, and *in vivo* animal studies to be involved in multiple processes with the potential to adversely affect bone remodelling. These include suppressing osteoblastic differentiation<sup>(8)</sup>, increasing osteoclastogenesis<sup>(9,10)</sup> and osteoclastic differentiation<sup>(10,11)</sup>, and activating the transcription factor NF- $\kappa$ B, which is involved in bone resorption signalling<sup>(11)</sup>. Thus, the potenti independent antioxidant activity of carotenoids has the potential to reduce bone resorption and lower fracture risk<sup>(12)</sup>. *In vitro* studies suggest that carotenoids may also have direct stimulatory effects on osteoblast proliferation and differentiation<sup>(13-15)</sup>.

A number of epidemiological studies have investigated links between carotenoids and bone health. There is some evidence of associations between higher specific carotenoid intakes and greater bone density<sup>(16-19)</sup> or lower incidence of hip fractures<sup>(20,21)</sup>, and of higher plasma carotenoid concentrations being associated with greater bone density<sup>(22)</sup> and a lower risk for developing osteoporosis<sup>(23,24)</sup>. However, these studies have had limited generalisability because of their focus on discrete population groups with a small cohort size, and on predominantly non-European participants. The current study thus aimed to explore potential associations of dietary carotenoid intakes and plasma concentrations ( $\alpha$ -carotene,  $\beta$ -carotene,  $\beta$ -cryptoxanthin, lutein and zeaxanthin, and lycopene) with the bone density status and risk for osteoporotic fractures in a general UK population of middle-aged and older men and women. This was achieved using data from a large prospective cohort and performing cross-sectional analysis of broadband ultrasound attenuation (BUA) of the heel bone in addition to longitudinal analysis of the occurrence of incident fractures of the hip, spine and the wrist.

### Methods

# Study population

The European Prospective Investigation into Cancer and Nutrition (EPIC) was established as a collaboration involving ten Western European countries. EPIC-Norfolk is one of the UK subcohorts, described in detail previously<sup>(25)</sup>. A baseline health check was attended by 25 639 free-living men and women aged 39–79 years between 1993 and 1997. A second health check was attended by 17 304 of the participants aged 42–82 years between 1998 and 2000. The Norfolk District Health Authority Ethics Committee approved all procedures and written informed consent was provided by participants according to the Declaration of Helsinki.

# Exposure variables

**Dietary carotenoids.** Daily dietary intakes of  $\alpha$ -carotene,  $\beta$ -carotene,  $\beta$ -cryptoxanthin, lutein and zeaxanthin, lycopene, and preformed retinol, were estimated from 7-d food diaries using the methodology described below for dietary covariates.

*Plasma carotenoids*. Blood was sampled by peripheral venepuncture at baseline, and plasma fractions with sodium citrate were stored in liquid N<sub>2</sub> at  $-196^{\circ}$ C until analysis by reversedphase HPLC to determine plasma concentrations of  $\alpha$ -carotene,  $\beta$ -carotene,  $\beta$ -cryptoxanthin, lutein and zeaxanthin, lycopene, and retinol<sup>(26)</sup>.

The correlation between matched dietary and plasma continuous scale variables was assessed using Pearson's correlation coefficient.

### Covariates

At each health check, height and weight were recorded according to standard protocols<sup>(25)</sup>, and participants completed a health and lifestyle questionnaire. Smoking status was categorised as current, former or never; family history of osteoporosis was categorised as yes or no; menopausal status (women only) was categorised as premenopausal, perimenopausal (<1 year), perimenopausal (1-5 years) or postmenopausal; and hormone replacement therapy (HRT) status (women only) was categorised as current, former, or never users. Physical activity over the preceding 12 months was assessed using a questionnaire, which placed participants into inactive, moderately inactive, moderately active and active categories using a method validated against heart-rate monitoring data<sup>(27)</sup>. A 7-d food diary was used to estimate the dietary intake of each participant<sup>(28)</sup>; participants recorded the quantity and type of all food, drink and supplements consumed within a 7-d period. Validation has shown this to be more accurate in estimating dietary nutrient intake than FFO<sup>(25,29)</sup>. DINER (Data Into Nutrients for Epidemiological Research) software was used to record the 7-d food diary information<sup>(30)</sup>, before further translation of the data for nutrient analysis using DINERMO<sup>(31)</sup>. All data entries were checked by nutritionists trained in use of the system<sup>(31)</sup>. The contribution of supplements was quantified using the Vitamin and Mineral Supplement (ViMiS) database<sup>(32)</sup>.

#### Outcome variables

Quantitative ultrasound measurements of the calcaneus (heel bone) were taken at the second health check using a contact ultrasound bone analyser (CUBA) device (McCue Ultrasonics) following standard protocols. BUA (dB/MHz) measurements were taken at least in duplicate for each foot of the participant, and the mean of the left and right foot measures was used for analysis. Each of the five CUBA devices used in the study was calibrated daily with its physical phantom. In addition, calibration between devices was checked monthly using a roving phantom. The CV was 3.5%. The CUBA method of bone density assessment has been shown to be capable of predicting fracture risk<sup>(33)</sup>, and is cheaper and simpler to conduct in general practice settings compared with the gold-standard of dual X-ray absorptiometry.

Fracture incidence data were collected using questionnaires at each health check, and the East Norfolk Health Authority database (ENCORE) of hospital attendances by Norfolk residents was also available for data linkage to corroborate selfreported data<sup>(34)</sup>. Incidence of all osteoporotic fractures in the cohort, up to the end of March 2009, was thus determined by retrieving data using each participant's National Health Service (NHS) number and by searching for events logged using



Fig. 1. Study population flow chart. HRT, hormone replacement therapy.

the International Classification of Diseases 9 and 10 diagnostic codes for osteoporotic hip, spine or wrist fractures (the three most common sites of osteoporotic fracture<sup>(35)</sup>).

# Statistical analysis

The High Performance Computing Cluster supported by the Research and Specialist Computing Support service at the University of East Anglia was used for statistical data analysis with STATA software (version 13; StataCorp LP.). A previous study of this population has shown sex-specific differences in age-related changes in bone, with greater deterioration evident in women<sup>(33)</sup>, and thus stratification by sex was used in all our analyses. Differences between values of variables for men and women were tested using the *t* test for continuous variables or the  $\chi^2$  test for categorical variables. *P*<0.05 was considered to be statistically significant in individual analyses.

### Cross-sectional analyses

Cross-sectional analyses were conducted using data taken at the second health check, combined with dietary or plasma data from the first health check; 14803 participants had complete data for diet and ultrasound analyses, and 4570 had complete data for plasma and ultrasound analyses (see Fig. 1). Multivariable adjusted regression with ANCOVA was used to investigate differences in calcaneal BUA across sex-specific dietary intake quintiles of carotenoid or preformed retinol. Trend testing was achieved by treating the median values for quintiles as a continuous variable<sup>(36)</sup>. Each model was adjusted for important biological, lifestyle and dietary factors: age, BMI, family history of osteoporosis, menopausal and HRT status in women, corticosteroid use, smoking status, physical activity, Ca intake, total energy intake, and Ca- and vitamin D-containing supplement use, known to influence BUA in this population<sup>(33,37–40)</sup>. To help correct for dietary misreporting, the days of food diary completed and the ratio of energy intake: estimated energy requirement<sup>(41)</sup> were included in all diet models. A number of different models were also tested for comparison purposes: models using residual adjustment for energy intake<sup>(42)</sup> where we adjusted for energy before defining the nutrient quintiles, in place of using unadjusted nutrient quintiles and adding energy as a covariate in the regression model; models including dietary fat or fibre as covariates as evidence suggests that these may affect dietary carotenoid absorption<sup>(43)</sup>; models including a variable quantifying total fruit and vegetable intake; and models combining food and supplement intakes, as excluding supplements may underestimate total nutrient intake<sup>(44)</sup>. Least square means for each quintile were calculated for all models. To minimise missing data exclusions, some missing values were recoded as follows: missing menopausal status data (2.8%) as premenopausal if age <50 years and never-user of HRT, or as postmenopausal if age >55 years or a current or former HRT user; missing smoking status data (0.7%) as former smokers. Participants missing data

for other variables in the multivariable model were excluded. In separate analyses, calcaneal BUA was investigated across sexspecific plasma concentration quintiles of specific carotenoids in a model with the covariates described above, but excluding dietary and supplement use data.

# Longitudinal analyses

Longitudinal analyses used data from the first health check together with data of hospital recorded fractures for the cohort participants (all cohort hip, spine and wrist fracture cases up to 31 March 2009; follow-up time was calculated as the time between an individual's first health check and this cut-off date, or death if earlier); data for diet and fracture analyses were available for 25439 participants, and for plasma and fracture analyses for 7474 participants (see Fig. 1). The Prenticeweighted Cox regression was used to investigate associations between incidence of fractures and sex-specific quintiles of specific carotenoid or retinol dietary intakes, or plasma concentrations, using the same adjustments as for the BUA models. Missing values were treated in the same way as in the BUA models. Total risk for hip, spine or wrist fracture was calculated as the risk for the first occurrence of one of these fractures; this does not consider multiple fractures, and therefore the sum of the specific-site fracture incidences does not sum to the total.

#### Results

Selected characteristics are summarised in Table 1. The significant differences evident according to sex supports our use of sex-specific model analyses. Mean dietary and supplementderived intakes of specific carotenoids and preformed retinol are shown for the study population ( $\alpha$ -carotene,  $\beta$ -cryptoxanthin, lutein and zeaxanthin, and lycopene supplement contributions were negligible; individual means  $\leq 150 \text{ ng/d}$ ). However, no UK Reference Nutrient Intake values<sup>(45)</sup> for carotenoids are currently available for comparison. Retinol plasma concentrations <100 µg/l are considered to indicate severe deficiency; 100–200 µg/l indicates mild deficiency<sup>(46)</sup>. Three individuals (0.07%) with plasma carotenoid data in the ultrasound cohort (n 4570) were mildly deficient according to these criteria and one (0.02%) was severely deficient; eleven individuals (0.15%) of the fracture cohort with plasma data (n 7474) were mildly deficient and three (0.04%) were severely deficient.

# Correlations between dietary carotenoid intakes and plasma concentrations

A number of weak, but significant, correlations were identified between dietary carotenoid intakes and plasma concentrations. Dietary  $\alpha$ -carotene intake was significantly correlated with plasma  $\alpha$ -carotene concentration in both men (r 0.497, P < 0.001, n 2355, ultrasound cohort; r 0.496, P < 0.001, n 2380, fracture cohort) and women (r 0.373, P < 0.001, n 2201, ultrasound cohort; r 0.368, P < 0.001, n 2219, fracture-case cohort). Dietary  $\beta$ -carotene intake was significantly correlated with plasma  $\beta$ -carotene concentration in both men (r 0.311, P < 0.001, n 2355, ultrasound cohort; r 0.311, P < 0.001, n 2380, fracture cohort) and women (r 0.280, P < 0.001, n 2301, ultrasound cohort; r = 0.275, P < 0.001, n = 2219, fracture-case cohort). Dietary  $\beta$ -cryptoxanthin intake was significantly correlated with plasma  $\beta$ -cryptoxanthin concentration in both men (*r* 0·395, *P* < 0·001, *n* 2355, ultrasound cohort; *r* 0·397, *P* < 0·001, n 2380, fracture cohort) and women (r 0.390, P < 0.001, n 2201) ultrasound cohort; r 0.388, P<0.001, n 2219, fracture-case cohort). Dietary lutein and zeaxanthin intake was significantly correlated with plasma lutein and zeaxanthin concentration in both men (r 0.211, P < 0.001, n 2355, ultrasound cohort; r 0.212, P < 0.001, n 2380, fracture cohort) and women (r 0.214, P < 0.001, *n* 2201, ultrasound cohort; *r* 0.212, P < 0.001, *n* 2219, fracture cohort). Dietary lycopene intake was significantly correlated with plasma lycopene concentration in both men  $(r \ 0.275, P < 0.001, n \ 2355, ultrasound cohort; r \ 0.279,$ P < 0.001, n 2380, fracture cohort) and women (r 0.294, *P*<0.001, *n* 2201, ultrasound cohort; *r* 0.293, *P*<0.001, *n* 2219, fracture cohort). Preformed dietary retinol intake was not significantly correlated with plasma retinol concentration in either men (r 0.039, P=0.056, n 2355, ultrasound cohort; r 0.038, P = 0.062, n 2380, fracture cohort) or women (r 0.013,P = 0.539, n 2201, ultrasound cohort; r 0.014, P = 0.516, n 2219, fracture cohort).

# Associations between dietary carotenoid intakes and bone density

Mean calcaneal BUA values stratified by sex and quintiles of specific dietary carotenoid or by preformed retinol intakes are shown in Fig. 2 for the fully adjusted model (unadjusted data are shown in the online Supplementary Table S1). In women, significant positive linear trends were apparent across quintiles of  $\alpha$ -carotene intake (P = 0.029),  $\beta$ -carotene intake (P = 0.003),  $\beta$ -cryptoxanthin intake (P=0.031), combined lutein and zeaxanthin intakes (P=0.010), and lycopene intake (P=0.005) for fully adjusted BUA; a significant negative trend was apparent across retinol intake quintiles (P=0.037). Individual significant differences in fully adjusted BUA in different quintiles v. quintile 1 were also identified for women for quintile 3 (1.5% higher;  $n \, 1662, P = 0.023$ ) and quintile 5 (2.3% higher;  $n \, 1662, P = 0.001$ ) for  $\beta$ -carotene intake; and for quintile 4 (1.8% higher; *n* 1663, P=0.007) and quintile 5 (1.7% higher; n 1662, P=0.011) for combined lutein and zeaxanthin intake (see Fig. 2). The associations described between BUA and carotenoid intake were no different when food and supplement contributions were combined in the model, except that with the combined intake data no trend in BUA across retinol quintiles was evident.

# Associations between plasma carotenoid concentrations and bone density

Analysis of bone density measures according to plasma carotenoid concentration quintiles, adjusting for all covariates previously described, with the exception of dietary factors, showed no significant linear trends in BUA for either men or women (see Fig. 3). Nevertheless, a significant difference in fully adjusted BUA was identified for men between quintile 2 and quintile 1 for plasma lutein and zeaxanthin (3.2% higher; n 473, P=0.015). Unadjusted data are shown in the online Supplementary Table S2. Table 1. Selected characteristics of the ultrasound analysis cohort (*n* 14 803) and the fracture cohort (*n* 25 439) from European Prospective Investigation into Cancer and Nutrition-Norfolk, stratified by sex (Mean values and standard deviations; numbers and percentages)

			Ultrasound cohor	ť*				Fracture cohort†		
	Men (	n 6490)	Women	( <i>n</i> 8313)		Men (n	11510)	Women (	n 13929)	
Selected characteristics	Mean	SD	Mean	SD	<i>P</i> ‡	Mean	SD	Mean	SD	<i>P</i> ‡
Age (years)	62.9	9.0	61.6	9.0	<0.001	59.7	9.3	58.9	9.3	<0.001
BMI (kg/m <sup>2</sup> )	26.9	3.3	26.5	4.4	<0.001	26.5	3.3	26.2	4.3	<0.001
BUA (dB/MHz)	90.1	17.5	72·1	16.5	<0.001					
Dietary-derived intake										
a-Carotene (μg/d)	406	363	403	356	0.601	390	366	389	387	0.862
β-Carotene (μg/d)	2069	1207	2036	1206	0.108	1988	1220	1958	1291	0.061
$\beta$ -Cryptoxanthin ( $\mu$ g/d)	406	569	455	570	<0.001	378	574	426	557	<0.001
Lutein and zeaxanthin (µg/d)	1095	870	1136	930	0.006	1048	884	1087	1013	0.001
Lycopene (µg/d)	1428	1671	1289	1365	<0.001	1385	1750	1238	1470	0.001
Retinol (µg/d)§	773	1297	622	1159	<0.001	780	1571	610	1239	<0.001
Ca intake (mg/d)	942	289	784	243	<0.001	919	298	766	249	<0.001
Total energy intake (kJ/d)	9560	2100	7242	1586	<0.001	9372	2205	7088	1653	<0.001
Total energy intake (kcal/d)	2285	502	1731	379	0001	2240	527	1694	395	0.001
Supplement-derived intake	2205	502	1751	575		2240	521	1094	395	
β-Carotene (μg/d)	39	673	68	833	0.023	41	706	65	804	0.012
Retinol (µg/d)	202	402	256	421	<0.001	180	383	238	417	<0.001
Ca-containing supplement use					<0.001					<0.001
n	1	02	50	05		16	35	7	46	
%		·6	6			1			-4	
Vitamin D-containing supplement use	I	0	0	1	<0.001		7	0	-	<0.001
n	16	21	27	72	<0.001	25	70	10	73	<0.001
%		5.0	33				2.3		).7	
Plasma concentration	2.	5.0		/- <del>-</del>		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	.0	00		
<i>α</i> -Carotene (μg/l)	771	57	102¶	69	<0.001	72**	56	97††	74	<0.001
	2001	124	267¶	162	<0.001	192**	120	257††	161	<0.001
$\beta$ -Carotene ( $\mu$ g/l)		61		86		72**				
$\beta$ -Cryptoxanthin ( $\mu$ g/l)	76		108¶		<0.001		59	105††	90	<0.001
Lutein and zeaxathin (µg/l)	198	85	211¶	94	<0.001	192**	85	209††	96	<0.001
Lycopene (µg/l)	3001	177	320¶	183	<0.001	290**	196	307††	184	<0.001
Retinol (µg/l)	5281	122	497¶	120	<0.001	525**	128	501††	127	<0.001
Smoking					<0.001					<0.001
Current										
n		55	72			14		16		
%	8	·6	8	-7		12	2-8	12	2-1	
Former										
n	36	609	26	97		62	33	44	46	
%	55	5.6	32	2.4		54	-2	31	.9	
Never										
п	23	326	48	95		38	06	77	92	
%		5.8	58			33			5.9	
Physical activity					<0.001					<0.001
Inactive					0001					0001
n	17	'92	21	88		35	10	10	32	
%		7.6	26						).4	
Moderately inactive	2		20			30		30	<b>т</b>	
-	10	26	07	14		00	00		60	
n			27			28			69	
%	28	5-1	32	0		24	-6	32	2-1	
Moderately active				~~			- 0		~~	
n		615	19			26			96	
%	24	4.9	23	3.9		23	3-0	22	.2	

Carotenoid intake, bone status and fractures

### Table 1. Continued

			Ultrasound cohort*	T				Fracture cohort†		
	Men (n	6490)	Women (	n 8313)		Men ( <i>n</i> 1	1510)	Women (n	13 929)	
Selected characteristics	Mean	SD	Mean	SD	<i>P</i> ‡	Mean	SD	Mean	SD	<i>P</i> ‡
Active										,
	145	7	142	21		247	8	213	2	
n %	22.	5	17.			21.	5	15-3		
Family history of osteoporosis					0.001					0.001
No										
n	631		779			112		1312		
%	97-	3	93-	7		97.	3	96.6	3	
Yes										
n	177		52			30		809		
%	2.7		6-3	3		2.7	·	3.4		
Corticosteroid use					0.391					0.077
Current or former (>3 months)	272		10	<u>^</u>		05		480		
n %	4.2		42 5-1			35 <sup>-</sup> 3-0		3.4		
Never (<3 months)	4.2		2.			3.0	)	3.4		
	621	0	788	7		11 1	50	1344	0	
n %	95-		94.			97.		96.6		
/o Menopausal status	30.	5	54.	5		57.	0	90.0	)	
Premenopausal										
n			48	4				234	>	
%			5.8					16-8		
Perimenopausal (<1 year)										
n			27	2				754		
%			3.3	3				5.4		
Perimenopausal (1–5 years)										
n			146	51				249	4	
%			17.	6				17.9	)	
Postmenopausal										
n %			609	6				833	9	
			73-	3				59.9	)	
Hormone replacement therapy										
Current										
n			176					282		
%			21.	2				20.3	3	
Former				-					_	
n			149					158		
%			17.	9				11-4	ł	
Never									-	
n			505					952		
%			60-	9				68-4	ł	

BUA, broadband ultrasound attenuation.

\* Ultrasound group characteristics at second health check (time of ultrasound).

† Fracture group characteristics at first health check or time of consent.

‡ Differences between men and women using *t* test for continuous or  $\chi^2$  for categorical variables.

§ Retinol as preformed intake only.

∥ *n* 2362.

¶ n 2208.

\*\* *n* 3817.

†† *n* 3657.

6

R. P. G. Hayhoe et al.



 Fig. 2. Fully adjusted cal

 Nutrition-Norfolk cohort, s

 and hormone replaceme

 D-containing supplement

 means and standard devia

 (sD 36) µg/d; Q2, 188 (sr

 (SD 40) µg/d; Q3, 337 (sp

 Q2, 1366 (sp 146) µg/d; (sp 139) µg/d; Q3, 1832

Fig. 2. Fully adjusted calcaneal broadband ultrasound attenuation (BUA) of 6490 men and 8313 women from the European Prospective Investigation into Cancer and Nutrition-Norfolk cohort, stratified by sex and dietary intake quintiles (Q) of specific carotenoids or retinol. Full model: age, BMI, family history of osteoporosis, menopausal and hormone replacement therapy status in women, corticosteroid use, smoking status, physical activity, calcium intake, total energy intake, calcium- and vitamin D-containing supplement use, days of food diary completed, and the ratio of energy intake:estimated energy requirement. Retinol as preformed intake only. Values are means and standard deviations represented by vertical bars. 🔲, Q1; 🥅, Q2; 🔲, Q3; 🔲, Q4; 🦳, Q5. Mean a-carotene intake per quintile: men – 406 (sp 363) µq/d; Q1, 40 (sp 36) µg/d; Q2, 188 (sp 41) µg/d; Q3, 339 (sp 46) µg/d; Q4, 515 (sp 60) µg/d; Q5, 948 (sp 399) µg/d; women – 403 (sp 356) µg/d; Q1, 50 (sp 40) µg/d; Q2, 196 (sp 40) μg/d; Q3, 337 (sp 44) μg/d; Q4, 509 (sp 60) μg/d; Q5, 922 (sp 416) μg/d. Mean β-carotene intake per quintile: men – 2069 (sp 1207) μg/d; Q1, 757 (sp 254) μg/d; Q2, 1366 (sp 146) µg/d; Q3, 1871 (sp 150) µg/d; Q4, 2472 (sp 212) µg/d; Q5, 3877 (sp 1199) µg/d; women – 2036 (sp 1206) µg/d; Q1, 758 (sp 247) µg/d; Q2, 1352 (sp 139) μg/d; Q3, 1832 (sp 142) μg/d; Q4, 2428 (sp 206) μg/d; Q5, 3813 (sp 1294) μg/d. Mean β-cryptoxanthin intake per quintile: men – 406 (sp 569) μg/d; Q1, 15 (sp 9) µg/d; Q2, 56 (sp 17) µg/d; Q3, 168 (sp 52) µg/d; Q4, 447 (sp 123) µg/d; Q5, 1343 (sp 622) µg/d; women – 455 (sp 570) µg/d; Q1, 25 (sp 13) µg/d; Q2, 89 (sp 29) µg/d; Q3, 243 (sp 61) µg/d; Q4, 540 (sp 124) µg/d; Q5, 1380 (sp 613) µg/d. Mean lutein and zeaxanthin intake per quintile: men – 1095 (sp 870) µg/d; Q1, 334 (sp 127) µg/d; Q2, 642 (sp 72) µg/d; Q3, 899 (sp 80) µg/d; Q4, 1244 (sp 130) µg/d; Q5, 2355 (sp 1144) µg/d; women – 1136 (sp 930) µg/d; Q1, 363 (sp 123) µg/d; Q2, 659 (sp 71) µg/d; Q3, 915 (sp 80) µg/d; Q4, 1263 (sp 132) µg/d; Q5, 2482 (sp 1256) µg/d. Mean lycopene intake per quintile: men – 1428 (sp 1671) µg/d; Q1, 126 (sp 117) µg/d; Q2, 556 (sp 121) µg/d; Q3, 1028 (sp 160) µg/d; Q4, 1693 (sp 242) µg/d; Q5, 3735 (sp 2416) µg/d; women – 1289 (sp 1365) µg/d; Q1, 147 (sp 116) µg/d; Q2, 524 (sp 104) µg/d; Q3, 932 (sp 134) µg/d; Q4, 1546 (sp 233) µg/d; Q5, 3297 (sp 1764) µg/d. Mean retinol intake per quintile: men – 773 (sp 1297) µg/d; Q1, 177 (sp 52) µg/d; Q2, 295 (sp 29) µg/d; Q3, 403 (sp 35) µg/d; Q4, 561 (sp 68) µg/d; Q5, 2431 (sp 2212) µg/d; women – 622 (sp 1159) µg/d; Q1, 138 (sp 41) µg/d; Q2, 233 (sp 22) µg/d; Q3, 309 (sp 25) μg/d; Q4, 425 (sp 45) μg/d; Q5, 2004 (sp 2069) μg/d. \* *P* < 0.05 *v*. Q1, \*\* *P* < 0.01, according to ANCOVA.

# Associations between dietary carotenoid intakes and fracture risk

Fully adjusted total risk for hip, spine or wrist fractures showed a significant negative linear association in men with quintiles of dietary  $\alpha$ -carotene (*n* 11510, *P*=0.040) and  $\beta$ -carotene (*n* 11510, *P*=0.044) intake. A significant negative trend was also present in women for the association between wrist fracture risk and lutein and zeaxanthin intake quintiles (*n* 13929, *P*=0.022). Table 2 shows all trend *P* values and quintile 1 *v*. quintile 5 comparisons. In men, total hip, spine and wrist fracture risk was lower in  $\alpha$ -carotene intake quintile 5 v. quintile 1 (0.71; 95% CI 0.53, 0.95; P=0.020); and hip fracture risk was lower in  $\alpha$ -carotene intake quintile 3 v. quintile 1 (0.64; 95% CI 0.42, 0.99; P=0.046) and  $\beta$ -cryptoxanthin intake quintile 5 v. quintile 1 (0.65 (95% CI 0.42, 0.99); P=0.046). In women, hip fracture risk was lower in lutein and zeaxanthin quintile 4 v. quintile 1, (0.75; 95% CI 0.58, 0.98; P=0.032). A negative linear association was evident across preformed retinol intake quintiles for wrist fracture risk (n 11 510, P=0.005) in men. Also in men, compared with dietary retinol quintile 1, total fracture risk was lower in quintile 5 (0.71; 95% CI 0.52, 0.97; P=0.033); wrist



**Fig. 3.** Fully adjusted calcaneal broadband ultrasound attenuation (BUA) of 2362 men and 2208 women from the European Prospective Investigation into Cancer and Nutrition-Norfolk cohort, stratified by sex and plasma concentration quintiles (Q) of specific carotenoids or retinol. Full model: age, BMI, smoking status, physical activity, family history of osteoporosis, menopausal and hormone replacement therapy status in women, and corticosteroid use. Values are means and standard deviations represented by vertical bars.  $\square, Q1; \square, Q2; \square, Q3; \square, Q4; \square, Q5.$  Mean *a*-carotene per quintile: men – 77 (sp 57) µg/l; Q1, 25 (sp 8) µg/l; Q2, 46 (sp 5) µg/l; Q3, 65 (sp 6) µg/l; Q4, 89 (sp 9) µg/l; Q5, 160 (sp 73) µg/l; women – 102 (sp 69) µg/l; Q1, 35 (sp 11) µg/l; Q2, 61 (sp 6) µg/l; Q3, 85 (sp 8) µg/l; Q4, 120 (sp 12) µg/l; Q5, 208 (sp 72) µg/l. Mean *β*-carotene per quintile: men – 200 (sp 124) µg/l; Q1, 79 (sp 21) µg/l; Q2, 129 (sp 12) µg/l; Q3, 174 (sp 15) µg/l; Q4, 235 (sp 21) µg/l; Q5, 383 (sp 141) µg/l; women – 267 (sp 612) µg/l; Q1, 107 (sp 28) µg/l; Q2, 174 (sp 16) µg/l; Q3, 234 (sp 17) µg/l; Q4, 310 (sp 26) µg/l; Q5, 509 (sp 183) µg/l. Mean *β*-cryptoxanthin per quintile: men – 76 (sp 61) µg/l; Q1, 22 (sp 7) µg/l; Q2, 40 (sp 5) µg/l; Q3, 60 (sp 6) µg/l; Q4, 88 (sp 10) µg/l; Q5, 170 (sp 7) µg/l; Q1, 105 (sp 20) µg/l; Q1, 32 (sp 9) µg/l; Q2, 57 (sp 7) µg/l; Q4, 28 (sp 16) µg/l; Q5, 239 (sp 10) µg/l; Q4, 88 (sp 10) µg/l; Q5, 170 (sp 70) µg/l; Q1, 105 (sp 20) µg/l; Q2, 149 (sp 10) µg/l; Q3, 182 (sp 10) µg/l; Q4, 228 (sp 16) µg/l; Q5, 239 (sp 10) µg/l; Q1, 103 (sp 33) µg/l. Q2, 110 (sp 24) µg/l; Q3, 195 (sp 11) µg/l; Q2, 57 (sp 7) µg/l; Q3, 485 (sp 8) µg/l; Q1, 103 (sp 33) µg/l; Q2, 204 (sp 53) µg/l; Q4, 396 (sp 35) µg/l; Q1, 103 (sp 35) µg/l; Q2, 204 (sp 53) µg/l; Q4, 396 (sp 35) µg/l; Q4, 29 (sp 16) µg/l; Q3, 296 (sp 24) µg/l; Q3, 267 (sp 24) µg/l; Q3, 289 (sp 26) µg/l; Q3, 485 (sp 16) µg/l; Q3, 267 (sp 24) µg/l; Q3, 267 (sp 24) µg/l; Q3, 289 (sp 26) µg/l; Q3, 485 (sp 16) µg/l; Q3, 296 (sp 26) µg/l; Q4, 396 (sp

fracture risk was lower in quintile 4 (0.44; 95% CI 0.24, 0.81; P=0.008) and quintile 5 (0.33; 95% CI 0.17, 0.65; P=0.001); and spine fracture risk was lower in quintile 3 (0.56 (95% CI 0.33, 0.96); P=0.033).

The associations between carotenoid intakes and fracture risk were no different when food and supplement contributions were combined in the model. However, preformed retinol analyses showed a number of differences when supplements were included. There was no significant difference in total fracture risk in men between retinol quintile 1 and quintile 5 with the combined intake data, although the differences in risk between quintile 2 and quintile 1 (0.67; 95% CI 0.50, 0.90; P=0.008) and between quintile 3 and quintile 1 (0.72; 95% CI 0.53, 0.96; P=0.028) were significant. Other significant retinol inter-quintile

differences, in addition to those found in diet only analyses, were: wrist fracture risk for men in quintile 3 v. quintile 1 (0.37; 95% CI 0.20, 0.69; P=0.002); spine fracture risk for men in quintile 2 (0.31; 95% CI 0.17, 0.56; P=0.048), quintile 4 (0.59; 95% CI 0.36, 0.96; P=0.036) and quintile 5 (0.54; 95% CI 0.30, 0.97; P=0.040) v. quintile 1; and wrist fracture risk for women in quintile 5 v. quintile 1 (0.64; 95% CI 0.43, 0.96; P=0.031).

# Associations between plasma carotenoid intakes and fracture risk

In men, but not in women, there was a significant linear trend for lower hip fracture risk across plasma  $\alpha$ -carotene quintiles (P = 0.026) and plasma  $\beta$ -carotene quintiles (P = 0.027)

Table 2. Risk of hip, spine and wrist fractures in the European Prospective Investigation into Cancer and Nutrition-Norfolk cohort population at follow-up v. baseline, stratified by sex and dietary intake quintiles (Q) of specific carotenoids or retinol

(The Prentice-weighted Cox proportional hazard ratios and 95% confidence intervals)

						Fracture incide	nce and risk†					
		Total fractures	s		Hip fracture			Spine fracture			Wrist fracture	
Intakes (µg/d)	Incidence	Hazard ratio	o 95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI
Men												
a-Carotene Q1	111/2302	1.00	Ref.	57/2302	1.00	Ref.	33/2302	1.00	Ref.	28/2302	1.00	Ref.
Q5	85/2302	0.71*	0.53, 0.95	44/2302	0.71	0.47. 1.06	22/2302	0.61	0.35, 1.07	23/2302	0.79	0.45, 1.40
Total‡	467/11 510	071	000, 000	228/11510	071	0 17, 1 00	149/11510	001	000, 107	115/11510	0,0	0 10, 1 10
P <sub>trend</sub>		C	0.040		0.1	11		0.08	96		0.73	30
$\beta$ -Carotene												
Q1	103/2302	1.00	Ref.	55/2302	1.00	Ref.	31/2302	1.00	Ref.	23/2302	1.00	Ref.
Q5 Total	85/2302	0.77	0.57, 1.03	39/2302	0.70	0.46, 1.07	27/2302	0.78	0.46, 1.33	25/2302	0.93	0.52, 1.68
	467/11 510	c.	0.044	228/11510	0.18	21	149/11510	0.13	20	115/11510	0.54	10
$P_{\text{trend}}$ $\beta$ -Cryptoxanthin		L L	J·044		0.10	51		0.13	02		0.54	+0
Q1	102/2302	1.00	Ref.	59/2302	1.00	Ref.	22/2302	1.00	Ref.	25/2302	1.00	Ref.
Q5	79/2302	0.80	0.59, 1.08	36/2302	0.65*	0.42, 0.99	29/2302	1.38	0.78, 2.44	18/2302	0.69	0.37, 1.28
Total	467/11510		,	228/11510		,	149/11510		,	115/11510		,
P <sub>trend</sub>		C	D·115		0.1	90		0.84	16		0.08	38
Lutein and zeaxanthin												
Q1	96/2302	1.00	Ref.	48/2302	1.00	Ref.	31/2302	1.00	Ref.	26/2302	1.00	Ref.
Q5	81/2302	0.82	0.61, 1.12	41/2302	0.90	0.56, 1.38	25/2302	0.74	0.43, 1.27	20/2302	0.70	0.39, 1.27
Total	467/11 510	c.	0.143	228/11510	0.9	20	149/11510	0.13	21	115/2302	0.23	20
P <sub>trend</sub> Lycopene		C C	5.145		0.97	29		0.10	51		0.24	50
Q1	109/2303	1.00	Ref.	61/2303	1.00	Ref.	33/2303	1.00	Ref.	23/2303	1.00	Ref.
Q5	69/2302	0.79	0.58, 1.07	35/2302	0.85	0.56, 1.31	19/2302	0.67	0.38, 1.20	19/2302	0.83	0.44, 1.56
Total	467/11 510		,	228/11510		, -	149/11510		, -	115/11510		- ,
P <sub>trend</sub>		C	D·137		0.3	36		0.29	98		0.55	52
Retinol§												
Q1	105/2302	1.00	Ref.	41/2302	1.00	Ref.	40/2302	1.00	Ref.	29/2302	1.00	Ref.
Q5 Total	467/11 510	0.71*	0.52, 0.97	44/2302	1.11	0.70, 1.77	28/2302	0.61	0.36, 1.05	16/2302	0.33**	0.17, 0.65
IOTAI P <sub>trend</sub>	260/6538	<i>.</i>	D·106	228/11510	0.9	20	149/11510	0.40	14	115/11510	0.00	5
/omen		L L	0.100		0.9	00		0.40	74		0.00	5
a-Carotene												
Q1	233/2786	1.00	Ref.	142/2786	1.00	Ref.	42/2786	1.00	Ref.	73/2786	1.00	Ref.
Q5	223/2785	0.97	0.80, 1.16	127/2785	0.89	0.69, 1.13	53/2785	1.42	0.94, 2.15	72/2785	0.98	0.70, 1.37
Total	1165/13 929		,	665/13929		,	249/13929		,	398/13929		,
Ptrend		C	0.372		0.1	72		0.12	29		0.77	77
β-Carotene												
Q1	254/2786	1.00	Ref.	153/2786	1.00	Ref.	48/2786	1.00	Ref.	84/2786	1.00	Ref.
Q5	218/2785	0.88	0.73, 1.07	121/2785	0.81	0.63, 1.04	54/2785	1.29	0.86, 1.92	73/2785	0.87	0.63, 1.20
Total	1165/13929	<i>.</i>	0.340	665/13929	0.20	פר	249/13929	0.22	0.4	398/13 929	0.55	-0
$P_{\text{trend}}$ $\beta$ -Cryptoxanthin		L L	0.340		0.20	5		0.22	-4		0.55	00
Q1	260/2786	1.00	Ref.	154/2786	1.00	Ref.	60/2786	1.00	Ref.	86/2786	1.00	Ref.
Q5	223/2785	0.89	0.74, 1.07	120/2785	0.82	0.64, 1.04	45/2785	0.85	0.57, 1.26	84/2785	1.00	0.73, 1.36
Total	1165/13 929		· · ·, · · · ·	665/13929		,	249/13929		,	398/13 929		,
P <sub>trend</sub>		C	0.646		0.29	93		0.83	31		0.70	08
Lutein and zeaxanthin												
Q1	246/2786	1.00	Ref.	141/2786	1.00	Ref.	52/2786	1.00	Ref.	88/2786	1.00	Ref.
Q5	221/2785	0.93	0.78, 1.13	134/2785	1.01	0.79, 1.29	46/2785	1.00	0.66, 1.50	64/2785	0.72	0.52, 1.00
Total	1165/13929			665/13929			249/13929			398/13929		
P <sub>trend</sub>		C	0.123		0.54	45		0.88	34		0.02	22

						Fracture incidence and risk†	nce and risk†					
		Total fractures			Hip fracture			Spine fracture			Wrist fracture	
Intakes (µg/d)	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI
Lycopene												
, E	267/2787	1.00	Ref.	151/2787	1.00	Ref.	58/2787	1.00	Ref.	87/2787	1.00	Ref.
Q5	185/2785	0.92	0.76, 1.12	92/2785	0.89	0.68, 1.16	43/2785	1.08	0.72, 1.61	72/2785	0-99	0.71, 1.36
Total	1165/13929			665/13 929			249/13929			398/13929		
$P_{\text{trend}}$		0.150	50		0-097	197		0.475	75		0.700	00
Retinol§												
01 01	222/2786	1.00	Ref.	120/2786	1.00	Ref.	57/2786	1.00	Ref.	84/2786	1.00	Ref.
Q5 Total	240/2785 1165/13929	0.93	0.76, 1.14	149/2785 665/13 929	1.00	0.77, 1.31	44/2785 249/13.929	0.68	0.44, 1.05	72/2785 398/13.929	0.81	0.57, 1.15
Ptrend		0.449	19		0.864	164		0.171	71		0.194	34

P<0.01 v. Q1, according to ANCOVA. values referent \*\* P < 0.05.

and hormone history of osteoporosis, Full model: age, BMI,

replacement therapy status in women, corticosteroid use, smoking status, physical activity, Ca intake, total energy intake, Ca- and vitamin D-containing total. to the t , menopausal a days of food diary use. supplement

the first đ <u>.</u>0 risk

as preformed intake only

Retinol

of food diary completed and the ratio of energy intake estimated energy requirement. occurrence of one of these fractures and therefore the sum of the specific-site fracture incidences do not sum

(see Table 3). In women, fracture risk was significantly lower in  $\alpha$ -carotene quintile 3 than in quintile 1 in the fully adjusted model for both total fracture (0.70; 95 % CI 0.50, 0.96; P = 0.028) and hip fracture (0.63; 95% CI 0.41, 0.97; P = 0.035); hip fracture risk in women was also lower in plasma retinol quintile 4 v. quintile 1 (0.64; 95% CI 0.41, 0.99; P = 0.044).

# Discussion

This study has shown that significant associations between dietary carotenoid intake and a quantitative measure of bone density exist in a UK population cohort, after adjustment for important biological, lifestyle and other dietary covariates. In women, dietary intake quintiles of dietary  $\alpha$ -carotene,  $\beta$ -carotene,  $\beta$ -cryptoxanthin, combined lutein and zeaxanthin, and lycopene were all positively linearly associated with calcaneal BUA, such that individuals with a higher intake of each of these carotenoids had higher BUA measurements; preformed retinol was negatively associated. Significant associations of BUA with quintiles of plasma carotenoid concentration were much more limited, with no significant trends apparent, and only a single inter-quintile association evident for lutein and zeaxanthin in men. Nevertheless, the magnitude of the effects seen with the dietary analyses is highly relevant to bone health<sup>(33)</sup>; for example, the difference between the median  $\beta$ -carotene intakes in quintile 5 and quintile 1 for women (3462) and  $792 \mu g/d$ ) could be accounted for by the additional intake of just one small carrot and yet is associated with 2.3% greater BUA. Moreover, this study included longitudinal analysis of the risk for osteoporotic fracture, demonstrating significant linear trends for lower risk for wrist fracture across dietary retinol quintiles in men and dietary lutein and zeaxanthin quintiles in women, and lower hip fracture risk across plasma  $\alpha$ -carotene and  $\beta$ -carotene concentration quintiles in men. A number of significant differences in fracture risk were also shown between individual quintiles of dietary carotenoid intake or plasma concentration. These include lower total risk for hip, spine and wrist fracture in the highest v, the lowest intake quintiles of dietary  $\alpha$ -carotene in men, as well as lower hip fracture risk in the highest  $\beta$ -cryptoxanthin intake quintile in men and in higher lutein and zeaxanthin intake quintiles in women. This study is, to our knowledge, the first comprehensive epidemiological analysis of the relevance of specific dietary and plasma carotenoids with bone density status and risk for osteoporotic fractures in a large European mixed-sex cohort. The findings thus provide an important advance to the current research evidence.

Inclusion of a variable quantifying total fruit and vegetable intake in our regression models caused an attenuation of the associations of carotenoids with BUA (data not shown), suggesting potential effects of other components in fruit and vegetables in addition to carotenoids. However, despite this attenuation, the associations of carotenoids with BUA remained significant, indicating that the effects of carotenoids independent of total fruit and vegetable consumption are important. The mechanisms by which carotenoids may influence bone metabolism are not fully understood, although a number of theories have been proposed. Some, but not all, carotenoids

NS British Journal of Nutrition

Table 3. Risk of hip, spine and wrist fractures in the European Prospective Investigation into Cancer and Nutrition-Norfolk cohort population at follow-up v. baseline, stratified by sex and serum concentration quintiles (Q) of specific carotenoids or retinol

(The Prentice-weighted Cox proportional hazard ratios and 95% confidence intervals).

						Fracture incide	ence and risk	t				
		Total fractures			Hip fracture			Spine fracture			Wrist fracture	
Intakes (µg/l)	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI
Men												
a-Carotene												
Q1	32/764	1.00	Ref.	18/764	1.00	Ref.	9/764	1.00	Ref.	8/764	1.00	Ref.
Q5	28/763	0.69	0.41, 1.16	12/763	0.52	0.25, 1.11	9/763	0.92	0.35, 2.39	7/763	0.60	0.21, 1.73
Total‡	175/3817			88/3817			63/3817		- <i>.</i>	33/3817		
P <sub>trend</sub> β-Carotene		0.06			0-03			0-59			0.4	
Q1	33/764	1.00	Ref.	18/764	1.00	Ref.	10/764	1.00	Ref.	7/764	1.00	Ref.
Q5	41/763	1.00	0.62, 1.63	13/763	0.52	0.25, 1.09	16/763	1.65	0.72, 3.82	13/763	1.46	0.54, 3.90
Total	175/3817			88/3817			63/3817			33/3817		
P <sub>trend</sub>		0.74	14		0.03	27		0.1	51		0.3	60
$\beta$ -Cryptoxanthin												
Q1	29/764	1.00	Ref.	16/764	1.00	Ref.	10/764	1.00	Ref.	6/764	1.00	Ref.
Q5	35/763	1.12	0.68, 1.85	16/763	0.91	0.45, 1.85	15/763	1.53	0.67, 3.48	4/763	0.58	0.16, 2.09
Total	175/3817			88/3817			63/3817			33/3817		
P <sub>trend</sub>		0.65	55		0.2	82		0.3	60		0.2	39
Lutein and zeaxanthin			<b>-</b> <i>i</i>			<b>-</b> <i>i</i>			5 /			- <i>(</i>
Q1	29/764	1.00	Ref.	12/764	1.00	Ref.	16/764	1.00	Ref.	1/764	1.00	Ref.
Q5	37/763	1.07	0.65, 1.75	13/763	0.85	0.39, 1.90	18/763	1.04	0.52, 2.09	6/763	5.15	0.61, 43.4
Total	175/3817			88/3817		~~	63/3817		40	33/3817		
P <sub>trend</sub>		0.97	/0		0.8	09		0.84	40		0.9	47
Lycopene	44/704	4.00	Ξ.	07/704	4.00	Β.	10/701	4.00	Ε.	7/704	4.00	<b>D</b> (
Q1	44/764	1.00	Ref.	27/764	1.00	Ref.	12/764	1.00	Ref.	7/764	1.00	Ref.
Q5	29/763	0.79	0.49, 1.29	10/763	0.54	0.26, 1.13	15/763	1.40	0.64, 3.08	6/763	0.82	0.26, 2.57
Total	175/3817	0.00	20	88/3817	0.1	07	63/3817	0.5	20	33/3817	0.0	50
P <sub>trend</sub>		0.33	39		0.1	07		0.5	29		0.6	59
Retinol	42/764	1 00	Def	00/704	1.00	Ref.	10/704	1.00	Ref.	5/764	1.00	Def
Q1 Q5	42/764 34/763	1.00 0.76	Ref.	23/764 16/763	1.00 0.67		16/764 14/763	1.00 0.84		5/764 5/763	1.00 0.93	Ref.
Total	175/3817	0.76	0.49, 1.20	88/3817	0.07	0.35, 1.27	63/3817	0.04	0.41, 1.72	33/3817	0.93	0·27, 3·23
P <sub>trend</sub>	175/3017	0.29	20	00/3017	0.4	76	03/3017	0.4	00	33/3017	0.7	00
Vomen		0.23	33		0.4	/5		0.40	02		0.77	23
a-Carotene												
Q1	84/732	1.00	Ref.	50/732	1.00	Ref.	22/732	1.00	Ref.	24/732	1.00	Ref.
Q5	81/731	0.79	0.57, 1.08	47/731	0.74	0.49, 1.12	15/731	0.60	0.30, 1.20	32/731	1.15	0.66, 2.01
Total	386/3657	0.79	0.57, 1.00	232/3657	0.74	0.49, 1.12	89/3657	0.00	0.30, 1.20	121/3657	1.13	0.00, 2.01
Ptrend	300/3037	0.42	00	232/3037	0.2	85	09/3037	0.2	78	121/3037	0.2	41
$\beta$ -Carotene		0.42			0.20	00		0.2	10		0.2	<b>T</b> 1
Q1	56/732	1.00	Ref.	29/732	1.00	Ref.	20/732	1.00	Ref.	16/732	1.00	Ref.
Q5	78/731	0.96	0.67, 1.38	48/731	1.00	0.62, 1.63	15/731	0.50	0.25, 1.02	26/731	1.27	0.66, 2.45
Total	386/3657	0.30	0.07, 1.00	232/3657	1.00	0.02, 1.00	89/3657	0.00	0.23, 1.02	121/3657	1.77	0.00, 2.40
P <sub>trend</sub>	500,0007	0.3	78	202,0001	0.2	49	30,0007	0.1	60	121/0007	0.5	63
$\beta$ -Cryptoxanthin		0.01	-		0.2			0.10	~~		0.0	~~
Q1	73/732	1.00	Ref.	42/732	1.00	Ref.	17/732	1.00	Ref.	22/732	1.00	Ref.
Q5	85/731	0.98	0.72, 1.35	51/731	0.97	0.64, 1.46	15/731	0.75	0.37, 1.52	29/731	1.16	0.66, 2.04
Total	386/3657	0.00	<i>572</i> , 100	232/3657	0.07	007,140	89/3657	070	507, 102	121/3657	1.10	5 00, 2 04
P <sub>trend</sub>	000,0007	0.8	73	202,0007	0.6	51	00,0001	0.24	45	121/0007	0.1	80
' trend		0.01	0		0.0			0.2			0.1	

7		
_ (		
•		
Continuo		
- 5		
C		
~		
-		
•		
4		
-		

NS British Journal of Nutrition

						Fracture incidence and riskt	ince and risk†					
		Total fractures			Hip fracture			Spine fracture			Wrist fracture	
Intakes (µg/I)	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI	Incidence	Hazard ratio	95 % CI
Lutein and zeaxanthin	58/732	00.1	Bef	31/732	1.00	Ref	17/730	00.1	Raf	00/730	0.1	Raf
05 05	81/731	1.02	0.72, 1.44	55/731	1.20	0.77, 1.90	16/731	0.69	0.34, 1.40	22/731	0.86	0.46, 1.60
Total	386/3657			232/3657			89/3657			121/3657		
P <sub>trend</sub> I vconene		0.862	22		0.752	52		0.420	0		0.589	ŋ
Q1	99/732	1.00	Ref.	61/732	1.00	Ref.	20/732	1.00	Ref.	30/732	1.00	Ref.
Q5	63/731	0.85	0.62, 1.18	38/731	0.96	0.63, 1.46	14/731	0.97	0.48, 1.96	22/731	0.87	0.49, 1.54
Total	386/3657			232/3657			89/3657			121/3657		
P <sub>trend</sub> Betinol		0.733	33		0.971	71		0.974	4		0.575	5
Q1	71/732	1.00	Ref.	46/732	1.00	Ref.	12/732	1.00	Ref.	22/732	1.00	Ref.
Q5	79/731	1.00	0.72, 1.39	51/731	0.98	0.65, 1.46	21/731	1.51	0.74, 3.10	19/731	0.81	0.43, 1.50
Total	386/3657			232/3657			89/3657			121/3657		
$P_{\rm trend}$		0.695	15		0.473	73		0.279	0		0.495	5

have provitamin A activity and therefore may have effects on bone health via this mediator<sup>(7)</sup>, all have antioxidant activity likely to be protective of bone<sup>(12)</sup>, and members of the carotenoid family have also been shown experimentally to have direct stimulatory effects on osteoblast proliferation and differentiation at physiologically relevant concentrations<sup>(20)</sup>.

Our results suggest that the effects on bone health may differ for specific carotenoids, a situation also evident in previous carotenoid research<sup>(16,17,21)</sup>. In the Framingham Osteoporosis Study, participants had lower risk for hip fracture or nonvertebral fracture if they were in the highest tertile of total carotenoid or lycopene intake, respectively, but no associations were evident for  $\alpha$ -carotene or  $\beta$ -carotene,  $\beta$ -cryptoxanthin, or lutein and zeaxanthin<sup>(21)</sup>. It is possible that this occurrence may be due to differing ranges and magnitude of intakes for different carotenoids. Indeed, specific carotenoids are found in differing concentrations in different fruit and vegetables: unpublished composition analysis conducted for the EPIC-Norfolk cohort showed that  $\alpha$ -carotene was predominantly sourced from root vegetables, especially carrots (65% of total);  $\beta$ -carotene was also sourced significantly from carrots (35%) and other root, dark-green leafy and fruiting vegetables;  $\beta$ -cryptoxanthin was sourced from citrus fruits, mainly oranges; lutein was sourced mainly from peas (16%), with broccoli, cabbages and other leafy vegetables providing approximately 10% each; zeaxanthin was sourced mostly from citrus fruits (19% from oranges), apples (>10%) and green leafy and fruiting vegetables; and lycopene was sourced from fruiting vegetables, mainly tomatoes (35%) and tinned beans in tomato sauce (15%). However, it is also possible that underlying mechanisms of action may be different and more potent for some carotenoids compared with others. We know that all carotenoids are capable of antioxidant activity with potential to counter the negative influence of oxidative stress on bone health<sup>(12)</sup>, but some, for example,  $\beta$ -cryptoxanthin<sup>(7)</sup>, have been shown to have direct effects on bone metabolism. The fact that differing magnitudes of effects appear to exist leads us to speculate that universal antioxidant activity may not be the dominant mechanism for all carotenoids. Another factor is the potential for differential absorption, which may affect interpretation, but makes the plasma data presented in this study particularly useful. Indeed, although low serum concentrations of  $\alpha$ -carotene and  $\beta$ -carotene, lycopene,  $\beta$ -cryptoxanthin and zeaxanthin have been demonstrated in a study of Italian women with osteoporosis, and likewise for lycopene and  $\beta$ -cryptoxanthin in US women<sup>(12)</sup>, only one small Japanese study has been published detailing a longitudinal analysis of serum carotenoids and bone health, observing lower risk for osteoporosis development with higher serum  $\beta$ -carotene and  $\beta$ -cryptoxanthin<sup>(23)</sup>.

Our findings showed correlation between dietary intakes of carotenoids and their plasma concentrations, corroborating previous studies<sup>(47,48)</sup>. The relatively weak nature of these correlations has also been noted previously and attributed to various influences including seasonality, obesity and day to day variation in an individual's dietary intake and plasma concentrations<sup>(49)</sup>. No correlation was identified for dietary retinol intake and plasma retinol concentration. Between the extremes of severe

\*\*

13

deficiency and excess, plasma retinol is tightly homoeostatically controlled<sup>(50)</sup>, which could explain the lack of correlation with dietary intake in our data<sup>(44)</sup>. Our results for bone density status in women confirm the detrimental effects of higher dietary vitamin A retinol-equivalent intakes reported elsewhere<sup>(51)</sup>, and although not directly replicated in associations of diet and fracture risk, plasma retinol data corroborates this with a lower comparative risk for fracture in quintile 4 *v*. quintile 1 than in quintile 5 *v*. quintile 1.

# Strengths and limitations

This study provides important observational evidence of associations between specific carotenoid dietary intakes or plasma concentrations and bone health, in the largest European study on this subject to date. Nevertheless, we were limited in the data available for analysis. In particular, plasma carotenoid data were only available for a smaller subset of the full cohort, which may have reduced the power of our analyses. In terms of anthropometric indices, blood pressure and blood lipids, the EPIC-Norfolk cohort is representative of the UK population<sup>(25)</sup>. We acknowledge that hospital admission data may underestimate fracture incidence, particularly of spine fractures, and this could differ by sex. Furthermore, record linkage used to determine fracture cases precluded the ability to discriminate between low- and high-trauma fractures. The influence of this on our findings is expected to be small, as the proportion of high-trauma fracture cases in this demographic group is likely to be low<sup>(52)</sup>. It is an advantage of our study that data for both sexes were analysed, as different effects were evident in men and women, a situation often apparent in bone health. For example, data from a Chinese cohort study showed that total carotenoid and  $\alpha$ -carotene or  $\beta$ -carotene, and lutein/zeaxanthin were all inversely associated with hip fracture risk in men, but no significant associations were identified for women<sup>(20)</sup>. Our data similarly show the strongest associations for fracture risk in men, although the ultrasound data are conversely more significant in women. Sex differences in fruit and vegetable consumption or reporting may be responsible for differences in the associations with bone identified here and in previous studies<sup>(53)</sup>, although, as carotenoids are fat soluble, the different adiposity of men and women could also influence their bioavailability and effects.

Accurate estimation of dietary nutrient intake is critical to the validity of the findings of this type of study. The quantitative 7-d food diary method used here has been validated previously and is expected to provide more precise dietary intake figures compared with FFQ or 24-h recall methods<sup>(31)</sup>. Dietary and lifestyle data used in longitudinal analyses were collected at baseline, and thus variation in food consumption and lifestyle behaviours could have influenced our findings. We have focused our attention on models using nutrient composition data from food intake only; thus, we potentially underestimate total nutrient intakes, including supplements. Carotenoids from supplements have been suggested to have greater bioavailability than those derived from foods and thus may make an important contribution to plasma carotenoid concentrations<sup>(6)</sup>. In this cohort, no fundamental differences were apparent

between models combining food and supplement contributions and those using food contributions only, although some additional inter-quintile differences in fracture risk were apparent for preformed retinol analyses when supplements were included, a likely result of the extension of the upper intake range. Previous studies have shown that the absorption of carotenoids is positively associated with dietary lipid intake, in particular, MUFA intake, and it may also be affected by dietary fibre<sup>(43)</sup>. However, in our dietary BUA model, the effect of inclusion of dietary fat or fibre was minimal (data not shown). Food preparation may also affect carotenoid stability, which, combined with food carotenoid content variability due to cultivation practices, season and ripening status<sup>(6)</sup>, may have reduced the accuracy of carotenoid intake estimations from the food diaries used in this study. In addition to the direct influence of dietary carotenoid intake, plasma carotenoid concentrations are influenced by the rate of uptake into and efflux from other tissues<sup>(54)</sup>. Inter-individual variability in these processes may thus make plasma concentrations less reliable as a biomarker of dietary intake and may partly explain the discrepancies between diet and plasma results presented here. Indeed it has been suggested that adipose tissue concentrations are likely to give a better indication of long-term carotenoid status<sup>(55,56)</sup>. Metabolism and absorption of carotenoids, and thus their measurable plasma concentrations, may also be influenced by other physiological or lifestyle factors, including the inflammatory profile<sup>(57)</sup>, adiposity<sup>(58)</sup> and smoking<sup>(59)</sup>. The inflammatory profile may be particularly relevant to the cohort analysed here, as chronic low-grade inflammation is common in older populations and thus should be investigated by future studies with reference to bone health.

### Conclusions

This study has shown positive associations of dietary intake and plasma concentration of specific carotenoids with a quantitative ultrasound measure of bone density status and lower fracture risk in a general population group. The results are insufficiently consistent to make definitive conclusions, but are nevertheless supportive of the hypothesis that dietary intakes of fruit and vegetables rich in carotenoids and other antioxidants are beneficial to adult bone, which, once confirmed by clinical trials, may provide a valuable approach for public health strategies to improve bone health in our ageing population.

# Acknowledgements

The authors thank the EPIC staff and the participants enrolled in the study.

The EPIC-Norfolk study received grants from the Medical Research Council (G9502233) and from Cancer Research UK (SP2024-0201 and SP2024-0204).

A. A. W. developed the research question with R. P. G. H. who analysed the data and drafted the manuscript. A. A. W. also arranged data collection in conjunction with R. N. L., who implemented record linkage. M. A. H. L. and A. A. M. prepared dietary and supplement data. K.-T. K. is the principal

investigator of the EPIC-Norfolk Study. All authors contributed to data interpretation, review of the manuscript and its approval.

None of the authors has any conflicts of interest to declare.

### Supplementary material

For supplementary material/s referred to in this article, please visit https://doi.org/10.1017/S0007114517001180

### References

- 1. Mitchell PJ, Cooper C, Dawson-Hughes B, *et al.* (2015) Lifecourse approach to nutrition. *Osteoporos Int* **26**, 2723–2742.
- Gennari C (2001) Calcium and vitamin D nutrition and bone disease of the elderly. *Public Health Nutr* 4, 547–559.
- Michaelsson K (2015) Calcium supplements do not prevent fractures. *BMJ* 351, h4825.
- 4. Hayhoe RP, Lentjes MA, Luben RN, *et al.* (2015) Dietary magnesium and potassium intakes and circulating magnesium are associated with heel bone ultrasound attenuation and osteoporotic fracture risk in the EPIC-Norfolk cohort study. *Am J Clin Nutr* **102**, 376–384.
- Finck H, Hart AR, Jennings A, *et al.* (2014) Is there a role for vitamin C in preventing osteoporosis and fractures? A review of the potential underlying mechanisms and current epidemiological evidence. *Nutr Res Rev* 27, 268–283.
- Arscott SA (2013) Food sources of carotenoids. In *Carotenoids and Human Health*, pp. 3–19 [SA Tanumihardjo, editor]. New York: Springer.
- Yamaguchi M (2012) Role of carotenoid beta-cryptoxanthin in bone homeostasis. J Biomed Sci 19, 36.
- 8. Mody N, Parhami F, Sarafian TA, *et al.* (2001) Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. *Free Radic Biol Med* **31**, 509–519.
- 9. Garrett IR, Boyce BF, Oreffo RO, *et al.* (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone *in vitro* and *in vivo*. *J Clin Invest* **85**, 632–639.
- Lee NK, Choi YG, Baik JY, *et al.* (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. *Blood* **106**, 852–859.
- Bai XC, Lu D, Liu AL, *et al.* (2005) Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. *J Biol Chem* 280, 17497–17506.
- Tanumihardjo SA & Binkley N (2013) Carotenoids and bone health. In *Carotenoids and Human Health*, pp. 237–245 [SA Tanumihardjo, editor]. New York: Springer.
- Kim L, Rao AV & Rao LG (2003) Lycopene II effect on osteoblasts: the carotenoid lycopene stimulates cell proliferation and alkaline phosphatase activity of SaOS-2 cells. *J Med Food* 6, 79–86.
- Park CK, Ishimi Y, Ohmura M, et al. (1997) Vitamin A and carotenoids stimulate differentiation of mouse osteoblastic cells. J Nutr Sci Vitaminol (Tokyo) 43, 281–296.
- Uchiyama S & Yamaguchi M (2005) Beta-cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells. *J Cell Biochem* **95**, 1224–1234.
- Wattanapenpaiboon N, Lukito W, Wahlqvist ML, *et al.* (2003) Dietary carotenoid intake as a predictor of bone mineral density. *Asia Pac J Clin Nutr* 12, 467–473.
- 17. Sahni S, Hannan MT, Blumberg J, *et al.* (2009) Inverse association of carotenoid intakes with 4-y change in bone mineral

density in elderly men and women: the Framingham Osteoporosis Study. Am J Clin Nutr 89, 416-424.

- Sugiura M, Nakamura M, Ogawa K, *et al.* (2011) Dietary patterns of antioxidant vitamin and carotenoid intake associated with bone mineral density: findings from post-menopausal Japanese female subjects. *Osteoporos Int* 22, 143–152.
- de Jonge EA, Kiefte-de Jong JC, Campos-Obando N, *et al.* (2015) Dietary vitamin A intake and bone health in the elderly: the Rotterdam Study. *Eur J Clin Nutr* 69, 1360–1368.
- Dai Z, Wang R, Ang LW, *et al.* (2014) Protective effects of dietary carotenoids on risk of hip fracture in men: the Singapore Chinese Health Study. *J Bone Miner Res* 29, 408–417.
- 21. Sahni S, Hannan MT, Blumberg J, *et al.* (2009) Protective effect of total carotenoid and lycopene intake on the risk of hip fracture: a 17-year follow-up from the Framingham Osteoporosis Study. *J Bone Miner Res* **24**, 1086–1094.
- 22. Sugiura M, Nakamura M, Ogawa K, *et al.* (2008) Bone mineral density in post-menopausal female subjects is associated with serum antioxidant carotenoids. *Osteoporos Int* **19**, 211–219.
- Sugiura M, Nakamura M, Ogawa K, *et al.* (2012) High serum carotenoids associated with lower risk for bone loss and osteoporosis in post-menopausal Japanese female subjects: prospective cohort study. *PLOS ONE* 7, e52643.
- 24. Yang Z, Zhang Z, Penniston KL, *et al.* (2008) Serum carotenoid concentrations in postmenopausal women from the United States with and without osteoporosis. *Int J Vitam Nutr Res* **78**, 105–111.
- Day N, Oakes S, Luben R, *et al.* (1999) EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. *Br J Cancer* **80**, Suppl. 1, 95–103.
- 26. Al-Delaimy WK, van Kappel AL, Ferrari P, *et al.* (2004) Plasma levels of six carotenoids in nine European countries: report from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutr* **7**, 713–722.
- 27. Wareham NJ, Jakes RW, Rennie KL, *et al.* (2003) Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Public Healtb Nutr* **6**, 407–413.
- 28. Bingham SA, Gill C, Welch A, *et al.* (1997) Validation of dietary assessment methods in the UK arm of EPIC using weighed records, and 24-hour urinary nitrogen and potassium and serum vitamin C and carotenoids as biomarkers. *Int J Epidemiol* **26**, Suppl. 1, S137–S151.
- 29. Riboli E, Hunt KJ, Slimani N, *et al.* (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* **5**, 1113–1124.
- 30. Welch AA, McTaggart A, Mulligan AA, et al. (2001) DINER (Data Into Nutrients for Epidemiological Research) – a new data-entry program for nutritional analysis in the EPIC-Norfolk cohort and the 7-day diary method. *Public Health Nutr* 4, 1253–1265.
- 31. Lentjes MA, McTaggart A, Mulligan AA, *et al.* (2013) Dietary intake measurement using 7 d diet diaries in British men and women in the European Prospective Investigation into Cancer-Norfolk study: a focus on methodological issues. *Br J Nutr*, 1–11.
- 32. Lentjes MA, Bhaniani A, Mulligan AA, *et al.* (2011) Developing a database of vitamin and mineral supplements (ViMiS) for the Norfolk arm of the European Prospective Investigation into Cancer (EPIC-Norfolk). *Public Health Nutr* **14**, 459–471.
- 33. Welch A, Camus J, Dalzell N, *et al.* (2004) Broadband ultrasound attenuation (BUA) of the heel bone and its correlates in men and women in the EPIC-Norfolk cohort: a cross-sectional population-based study. *Osteoporos Int* **15**, 217–225.

"

- Moayyeri A, Kaptoge S, Dalzell N, *et al.* (2009) Is QUS or DXA better for predicting the 10-year absolute risk of fracture? *J Bone Miner Res* 24, 1319–1325.
- Kanis JA, Oden A, Johnell O, *et al.* (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int* 12, 417–427.
- Chiuve SE, Sampson L & Willett WC (2011) The association between a nutritional quality index and risk of chronic disease. *Am J Prev Med* 40, 505–513.
- 37. Jakes RW, Khaw K, Day NE, *et al.* (2001) Patterns of physical activity and ultrasound attenuation by heel bone among Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): population based study. *BMJ* 322, 140.
- Willett WC, Howe GR & Kushi LH (1997) Adjustment for total energy intake in epidemiologic studies. *Am J Clin Nutr* 65, 12208–1228S; discussion 1229S–1231S.
- 39. Flynn A (2003) The role of dietary calcium in bone health. *Proc Nutr Soc* **62**, 851–858.
- Heaney RP (2000) Calcium, dairy products and osteoporosis. J Am Coll Nutr 19, 83S–99S.
- Institute of Medicine of the National Academies (2002) Dietary Reference Intakes for Energy, Carbobydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academies Press.
- 42. Willett W editor (1998) *Nutritional Epidemiology*, 2nd ed. New York: Oxford University Press.
- Goltz SR & Ferruzzi MG (2013) Carotenoid bioavailabiity: influence of dietary lipid and fiber. In *Carotenoids and Human Healtb*, pp. 111–128 [SA Tanumihardjo, editor]. New York: Springer.
- 44. Lentjes MA, Mulligan AA, Welch AA, *et al.* (2015) Contribution of cod liver oil-related nutrients (vitamins A, D, E and eicosapentaenoic acid and docosahexaenoic acid) to daily nutrient intake and their associations with plasma concentrations in the EPIC-Norfolk cohort. *J Hum Nutr Diet* **28**, 568–582.
- 45. Department of Health (1991) *Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report on Health and Social Subjects*, no. 41. London: HSMO.
- 46. World Health Organization (2011) Serum retinol concentrations for determining the prevalence of vitamin A deficiency in populations. Vitamin and Mineral Nutrition Information System. http://www.who.int/vmnis/indicators/ retinol.pdf (accessed December 2015).
- Brady WE, Mares-Perlman JA, Bowen P, *et al.* (1996) Human serum carotenoid concentrations are related to physiologic and lifestyle factors. *J Nutr* **126**, 129–137.

- 48. Talegawkar SA, Johnson EJ, Carithers TC, et al. (2008) Carotenoid intakes, assessed by food-frequency questionnaires (FFQs), are associated with serum carotenoid concentrations in the Jackson Heart Study: validation of the Jackson Heart Study Delta NIRI Adult FFQs. Public Health Nutr 11, 989–997.
- Scott KJ, Thurnham DI, Hart DJ, *et al.* (1996) The correlation between the intake of lutein, lycopene and beta-carotene from vegetables and fruits, and blood plasma concentrations in a group of women aged 50-65 years in the UK. *Br J Nutr* **75**, 409–418.
- Tanumihardjo SA (2011) Vitamin A: biomarkers of nutrition for development. *Am J Clin Nutr* 94, 6588–6658.
- Binkley N & Krueger D (2000) Hypervitaminosis A and bone. Nutr Rev 58, 138–144.
- 52. Finck H, Hart AR, Lentjes MA, *et al.* (2015) Cross-sectional and prospective associations between dietary and plasma vitamin C, heel bone ultrasound, and fracture risk in men and women in the European Prospective Investigation into Cancer in Norfolk cohort. *Am J Clin Nutr* **102**, 1416–1424.
- 53. Myint PK, Welch AA, Bingham SA, et al. (2007) Fruit and vegetable consumption and self-reported functional health in men and women in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk): a population-based crosssectional study. Public Health Nutr 10, 34–41.
- Burri BJ, Neidlinger TR & Clifford AJ (2001) Serum carotenoid depletion follows first-order kinetics in healthy adult women fed naturally low carotenoid diets. *J Nutr* **131**, 2096–2100.
- Wallstrom P, Wirfalt E, Lahmann PH, *et al.* (2001) Serum concentrations of beta-carotene and alpha-tocopherol are associated with diet, smoking, and general and central adiposity. *Am J Clin Nutr* **73**, 777–785.
- 56. Kardinaal AF, van 't Veer P, Brants HA, *et al.* (1995) Relations between antioxidant vitamins in adipose tissue, plasma, and diet. *Am J Epidemiol* **141**, 440–450.
- 57. Wood AD, Strachan AA, Thies F, *et al.* (2014) Patterns of dietary intake and serum carotenoid and tocopherol status are associated with biomarkers of chronic low-grade systemic inflammation and cardiovascular risk. *Br J Nutr* **112**, 1341–1352.
- Hosseini B, Saedisomeolia A & Skilton MR (2017) Association between micronutrients intake/status and carotid intima media thickness: a systematic review. *J Acad Nutr Diet* 117, 69–82.
- Handelman GJ, Packer L & Cross CE (1996) Destruction of tocopherols, carotenoids, and retinol in human plasma by cigarette smoke. *Am J Clin Nutr* 63, 559–565.